Background
Brian Binford was admitted to the Colorado Mental Health Hospital in Pueblo in February 2026 after being found incompetent to proceed in four pending criminal cases. He presented with delusions, response to internal stimuli, thought disorganization, disinhibition, impulsivity, agitation, and assaultive behavior, and was diagnosed with unspecified bipolar disorder. This was not his first admission: Binford had been hospitalized beginning in December 2024 with nearly identical symptoms and, after months of treatment with the antipsychotic Zyprexa (olanzapine) and the mood stabilizer Depakote (valproic acid), was restored to competency and released.
Upon readmission in February 2026, Binford began fighting, kicking, and spitting at staff and was placed in seclusion and restraint. The People petitioned the district court for authorization to involuntarily medicate him with Zyprexa, Haldol (haloperidol), Depakote, and Ativan (lorazepam). At the hearing, Binford refused to attend and his counsel waived his appearance. The sole witness was his treating psychiatrist, Dr. Hareesh Pillai, who testified that the requested medications were necessary both to prevent significant long-term deterioration of Binford’s severe bipolar disorder and to prevent the likelihood of him causing serious harm to others in the hospital.
The district court found Dr. Pillai’s testimony credible and persuasive, applied the four-part test from People v. Medina, 705 P.2d 961 (Colo. 1985), concluded the People had proven all four elements by clear and convincing evidence, and granted the petition. Binford appealed, challenging only the sufficiency of the evidence on the fourth Medina element — whether his compelling need for treatment overrides any bona fide and legitimate interest in refusing medication.
The Court’s Holding
The Colorado Court of Appeals affirmed, holding that the evidence was sufficient to support the district court’s finding that the fourth Medina element was satisfied. The court noted that Binford had conceded the second element — that the medications are necessary to prevent both significant long-term deterioration and a likelihood of serious harm to others — which substantially undermined his challenge to the fourth element’s balancing inquiry. Even assuming Binford held bona fide and legitimate reasons to refuse medication (avoiding sedation and other potential side effects), the court concluded those interests were outweighed by his compelling need for treatment.
The court emphasized that Dr. Pillai’s credited testimony established that Binford’s condition is severe, that Zyprexa and Depakote had successfully treated him during his prior hospitalization, that he was not currently experiencing side effects beyond some prior sedation, that no known underlying health conditions would be worsened by the medications, and that the risks of non-treatment exceeded the risks of treatment. Binford’s argument that Dr. Pillai could not accurately assess side effects because Binford refused to communicate with his treatment team was rejected as speculative, because the treatment team also monitored patients through observation, lab work, vital signs, and physical examinations — and because Binford did not appear at the hearing to offer any testimony about side effects he may have experienced.
The court also clarified in a footnote that the Medina test — rather than the federal Sell v. United States test for competency-restoration medication — applied here because the petition’s purpose was to prevent harm and deterioration, not solely to restore competency to stand trial.
Key Takeaways
- Under People v. Medina, Colorado courts may authorize involuntary medication upon clear and convincing proof of four elements; a patient’s concession of the necessity element (second prong) strongly supports satisfying the balancing element (fourth prong).
- The treating physician’s testimony alone can be sufficient to satisfy all four Medina elements, including the fourth element’s weighing of the patient’s refusal interests against the compelling need for treatment.
- Claimed side effects that are not currently manifesting — and that the patient cannot substantiate because he refused to appear at the hearing — are insufficient to establish a bona fide interest in refusal strong enough to override a compelling treatment need.
- The Medina test, not the federal Sell test, governs involuntary medication petitions aimed at preventing harm or deterioration, even when the patient was admitted for competency restoration purposes.
Why It Matters
This unpublished decision illustrates how Colorado appellate courts apply the Medina framework when a patient’s litigation posture works against him: by conceding that medication is necessary to prevent deterioration and serious harm to others, Binford effectively conceded much of the ground needed to defeat the fourth-element balancing test. Practitioners representing respondents in involuntary medication proceedings should carefully consider which elements to contest and ensure their clients appear at hearings, as a patient’s absence forecloses the very self-reporting evidence that might otherwise support claims of side effects or legitimate refusal interests.
The decision also provides a practical reminder that the choice between Medina and Sell turns on the petition’s stated purpose rather than the reason for the patient’s underlying hospitalization. Where a petition targets harm prevention and clinical stabilization rather than trial competency restoration, Medina‘s state-law standard controls, with its distinct four-part framework and clear-and-convincing burden.